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Abstract
Background: Myolipoma of soft tissue is an extremely rare benign tumor composed of mature adipose tissue
and smooth muscle cells. It is found predominantly in women. The cytogenetic and molecular genetic features
of myolipomas remain largely unexplored. Here we present the first cytogenetically analyzed myolipoma.
Methods: Cytogenetic and molecular genetic analyses were done on a myolipoma.
Results: G-banding analysis of short-term cultured cells from the myolipoma yielded a karyotype with a single clonal
chromosome abnormality: 46,XX,t(9;12)(p22;q14). Fluorescence in situ hybridization experiments demonstrated that
HMGA2 (in 12q14) was rearranged. Molecular genetic analysis showed that the translocation resulted in fusion of
HMGA2 with the C9orf92 gene (from 9p22). The HMGA2-C9orf92 fusion transcript would code for a putative protein
containing amino acid residues 1–94 of HMGA2 and 6 amino acid residues from the out-of-frame fusion with exon
4 of C9orf92.
Conclusion: The pattern of HMGA2 rearrangement in the present case of myolipoma is similar to what is found in
other benign connective tissue tumor types, including lipomas, i.e., disruption of the HMGA2 locus leaves intact exons
which encode the AT-hook domains but separates them from the 3´-terminal part of the gene. Whether any genetic
features differentiate myolipomas from regular lipomas with HMGA2-involvement is a question that cannot be answered
until more cases of the former tumor type are subjected to genetic analysis.
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Background
Myolipoma of soft tissue is a benign tumor composed of
mature adipose tissue and smooth muscle [1]. It was first
described as an entity in 1991 by Meis and Enzinger (as
myolipoma of soft tissue) [2] and Scurry et al. (as soft tis-
sue lipoleiomyoma) [3]. The tumor is extremely rare and
is found predominantly in women. Searching PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) using the term
“myolipoma” we found that around 50 cases have been
reported since 1991 (Additional file 1: Table S1; data
updated October 20, 2015). These tumors were found in
35 females and 14 males. The median age was 48 years
(range, 4–83) (Additional file 1: Table S1). Most publica-
tions have described single cases, further testifying to the
rarity of the disease. The tumor is usually found as a
deep-seated mass within the abdominal cavity, retroperi-
toneum, or inguinal region [2, 4–8], although other loca-
tions have been reported such as the tongue base,
mesentery, pericardium, and eyelid (Additional file 1:
Table S1). No cases with focal recurrence, metastatic
disease or other signs of malignant transformation
have been reported and cure is achieved by surgical
resection [1].
The cytogenetic and molecular genetic features of
myolipomas remain largely unexplored. In the 2013 edi-
tion of “WHO classification of tumours of soft tissue
and bone”, the only genetic information on these tumors
is that expression of full-length HMGA2 was detected by
RT-PCR in myolipoma of the pelvic cavity [1, 9].
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Here we present the first cytogenetically analyzed
myolipoma. The tumor had a t(9;12)(p22;q14) as the sole
karyotypic aberration resulting in fusion of HMGA2 with
the C9orf92 gene.
Methods
Ethical approval
The study was approved by the Regional Committee for
Medical and Health Research Ethics, South-East Norway
(REK Sør) http://helseforskning.etikkom.no). Written in-
formed consent was obtained from the patient. The con-
sent included acceptance that his clinical details be
published. The ethics committee’s approval included a
review of the consent procedure. All patient information
has been anonymized.
Patient
The patient is a 66 years old female who underwent an
abdominal CT-scan due to pain radiating into the left
lower extremity. The scan revealed a well demarcated,
lipogenic tumor in the left retroperitoneum measuring
almost 20 cm in greatest diameter, invoking a suspicion of
liposarcoma. The tumor was completely excised. The op-
eration specimen showed a lipomatous tumor which was
macroscopically well demarcated and without infiltrative
growth. Microscopic evaluation showed a lipomatous
tumor with areas with smooth muscle differentiation,
without signs of malignancy (Fig. 1a and b). There were
no suspect lipoblasts. Smooth muscle fibers showed posi-
tive reaction for desmin (Fig. 1c) and smooth muscle actin
(SMA) (Fig. 1d) by immunohistochemical examination.
MDM2 immunostaining was negative (Fig. 1e).
Chromosome banding analysis and Fluorescence in situ
hybridization (FISH)
Fresh tissue from a representative area of the tumor was
received and cells from it were short-term cultured and
analyzed cytogenetically as part of our diagnostic routine
as described elsewhere [10]. The karyotype was written
according to the International System for Human Cyto-
genetic Nomenclature (ISCN) 2013 guidelines [11].
Fig. 1 Microscopical image of the myolipoma. a and b) H&E stained slides 10X (a) and 20X (b) magnification with mature fat between bundles of
spindle cells, confirmed as smooth muscle fibers by immunohistochemical examination showing positive reaction for desmin (c) and smooth
muscle actin (SMA) (d). MDM2 immunostaining was negative (e)
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FISH analysis based on the karyotyping findings (see
below) was performed on metaphase plates as described
previously [10]. BAC clones were retrieved from the Hu-
man genome high-resolution BAC re-arrayed clone set (the
“32k set”; BACPAC Resources, http://bacpac.chori.org/
pHumanMinSet.htm). The “32k set” is mapped on the
UCSC Genome browser on Human May 2004 (NCBI/
hg17) assembly. Mapping data for the 32k human re-array
are available in an interactive web format (http://bacpac.
chori.org/pHumanMinSet.htm, from the genomic rearrays
page ) and are obtained by activation of the ucsc browser
track for the hg17 UCSC assembly from the “32k set”
homepage (http://bacpac.chori.org/genomicRearrays.php).
The BAC clones were selected according to physical and
genetic mapping data on chromosome 12 as reported on
the Human Genome Browser at the University of
California, Santa Cruz website (May 2004, http://
genome.ucsc.edu/). In addition, FISH mapping of the
clones on normal controls was performed to confirm their
chromosomal location. The clones used were RP11-
185 K16, (chr12:64103524–64274514), RP11-30I11 (chr
12:64178505–64349708), RP11-662G15 (chr12:64288763–
64498219), RP118B13 (chr12:64644968–64789255), RP11-
745O10 (chr12:64752327–64926193), and RP11-263A04
(chr12:64908453–65103538). All of them map to
chromosome subband 12q14.3 (Fig. 2a). DNA was
extracted, and probes were labelled with Fluorescein-
12-dCTP (PerkinElmer, Boston, MA, USA) and Texas
Red-5-dCTP (PerkinElmer) in order to obtain green and
red signals, respectively, using the Abott’s nick translation
kit (Des Plaines, IL, USA), and hybridized according to
Abbott Molecular recommendations (http://www.abbott-
molecular.com/home.html). A homemade breakapart
HMGA2 probe was used. The 5´-end of the probe (red
signal) was constructed from a pool of the clones RP11-
185K16, RP11-30I11, and RP11-662G15. The 3´-end of
the probe (green signal) was constructed from a pool of
the clones RP118B13, RP11-745O10, and RP11-263A04.
All of them map to chromosome subband 12q14.3 and
cover the HMGA2 locus (Fig. 2a).
Molecular analyses
Tumor tissue adjacent to that used for cytogenetic analysis
and histologic examination had been frozen and stored
at −80 °C. Total RNA was extracted using miRNeasy Mini
Kit according to the manufacturer’s instructions (Qiagen
Nordic, Oslo, Norway). Tumor tissue was disrupted and
homogenized in Qiazol Lysis Reagent (Qiagen) using
5 mm stainless steel beads and TissueLyser II (Qiagen).
Subsequently, total RNA was purified using QIAcube
(Qiagen). Human Universal Reference Total RNA was
used as control (Clontech Laboratories, TaKaRa-Bio
Group, Europe/SAS, Saint-Germain-en-Laye, France). Ac-
cording to the company’s information, it is a mixture of
total RNAs from a collection of adult human tissues
chosen to represent a broad range of expressed genes.
Both male and female donors are represented.
The 3´-RACE methodology was described in detail
elsewhere [10]. To verify the results obtained by 3´-
RACE, i.e., the presence of an HMGA2-C9orf92 chimeric
transcript (see below), RT-PCR was performed using the
forward HMGA2-936F1 (5´-AGC CCT CTC CTA AGA
GAC CCA G-3´) and the reverse C9orf92-316R1 (5´-
TGA AGT TTT AAT CAA CAC AAG CAG C-3´)
primers. Total RNA (1 μg) was reverse-transcribed in a
20 μL reaction volume using iScript Advanced cDNA Syn-
thesis Kit for RT-qPCR according to the manufacturer’s
instructions (Bio-Rad Laboratories, Oslo, Norway). The
25 μL PCR volume contained 12.5 μL Premix Ex Taq
DNA Polymerase Hot Start Version (Takara Bio), 1 μL of
cDNA, and 0.4 μM of each of the forward HMGA2-936F1
and reverse C9orf92-316R1 primers. PCR amplifications
were run on a C-1000 Thermal cycler (Bio-Rad Laborator-
ies) with an initial denaturation at 94 °C for 30 s, followed
by 35 cycles of 7 s at 98 °C, 30 s at 58 °C, 1 min at 72 °C,
and a final extension for 5 min at 72 °C. Three μL of the
PCR products were stained with GelRed (Biotium,
Hayward, CA, USA), analyzed by electrophoresis through
1.0 % agarose gel, and photographed. The remaining 22 μL
PCR products were purified using the MinElute PCR puri-
fication kit (Qiagen) and sequenced at GATC Biotech
(Germany, http://www.gatc-biotech.com/en/home.html).
The BLAST software (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) was used for computer analysis of sequence data.
Results
G-banding analysis
G-banding analysis of short-term cultured cells from
the myolipoma yielded a karyotype with a single clonal
chromosome abnormality: 46,XX,t(9;12)(p22;q14) [12]
(Fig. 2b).
FISH experiments showed that the HMGA2 probe was
split with one signal on der(12) and the other on der(9)
(Fig. 2c).
Molecular genetic analysis
3´-RACE analysis amplified a single fragment (Fig. 2d).
Subsequent Sanger sequencing showed that it was a
chimeric cDNA fragment in which exon 4 of HMGA2
from 12q14 (nt 1093 in the reference sequence with ac-
cession number NM_003483.4) was fused to exon 4 of
the C9orf92 gene from 9p22 (nt 261 in the reference se-
quence NM_001271829.1).
PCR with the primers HMGA2-936F1 and C9orf92-
316R1 amplified a cDNA fragment from myolipoma but
not from control (Fig. 2d). Direct sequencing of the PCR
product showed the same fusion breakpoint as that de-
tected in the 3´-RACE amplified fragment (Fig. 2e).
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Discussion
We describe the first cytogenetic and molecular genetic
analysis of a myolipoma. The tumor had an acquired
chromosomal translocation, t(9;12)(p22;q14), which re-
sulted in fusion of the C9orf92 (from 9p22) and HMGA2
(from 12q14) genes. The HMGA2-C9orf92 fusion tran-
script codes for a putative protein which contains amino
acid residues 1–94 of HMGA2 protein (accession number
NP_003474.1), corresponding to exons 1–4 of the gene,
and 6 amino acid residues (AHKEDT) coming from an
out-of-frame fusion with exon 4 of C9orf92.
Information on C9orf92 is very scant and nothing is
known about its cellular localization or function (http://
www.ncbi.nlm.nih.gov/gene/100129385). Two transcript
variants have been reported: Transcript variant 1 (reference
sequence NM_001271829) which represents the shorter
transcript and encodes a functional protein, and transcript
variant 2 (reference sequence NR_073471) which uses an
alternative 5' exon structure compared to variant 1. Tran-
script variant 2 is a non-coding RNA due to the presence
of an upstream open reading frame (ORF) that is
predicted to interfere with translation of the longest
ORF (http://www.ncbi.nlm.nih.gov/gene/100129385). C9orf92
is low expressed in many normal human tissues as
shown by RNA-sequencing (http://www.genecards.org/
cgi-bin/carddisp.pl?gene=C9orf92&keywords=c9orf92).
The translocation t(9;12)(p22;q14 ~ 15), or variants
thereof, was reported before in lipomas [12–15], uterine
leiomyomas [16, 17], chondroid hamartomas [18], and
pleomorphic adenomas [19]. In lipomas and pleomorphic
Fig. 2 Cytogenetic, FISH, and RT-PCR analyses of the myolipoma. a) Chromosome 12 ideogram showing the location of the HMGA2 locus and
the BACs used for FISH experiments. The investigated region is indicated as a red box. b) Partial karyotype showing the der(9)t(9;12)(p22;q14) and
der(12)t(9;12)(p22;q14) together with the corresponding normal chromosome homologs; breakpoint positions are indicated by arrows. c) FISH analysis
with an HMGA2 breakapart probe. The green signal (pool of the BACs RP118B13, RP11-745O10, and RP11-263A04) is moved to der(9) whereas the red
signal (pool of the BACs RP11-185K16, RP11-30I11, and RP11-662G15) is seen on der(12). d) Amplification of an HMGA2-C9orf92 cDNA fragment using
primers HMGA2-936F1 and C9orf92-316R1 in myolipoma (T) but not in control (C). M, 1 Kb DNA ladder (GeneRuler, Fermentas), Bl, Blank, water in cDNA
synthesis. e) Partial sequence chromatogram of the cDNA fragment showing the fusion of HMGA2 with C9orf92
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adenomas, a cytogenetically similar recombination be-
tween 9p and 12q was shown to result in the fusion of
HMGA2 with NFIB [12, 13, 15, 19] which maps 2.2 Mbp
distal to C9orf92.
In lipomas, two different HMGA2–NFIB fusion tran-
scripts have been identified. In the first type, exons 1–4 of
HMGA2 were fused to exon 9 of NFIB [12, 13, 15]. In the
second type, the fusion transcript consisted of the first
three exons of HMGA2, exon 6 of MSRB3 (12q14.3), and
exon 9 of NFIB [15]. In both transcript types, a stop codon
is present on the 3′ side shortly after the fusion point of
HMGA2 with NFIB or MSRB3 [12, 13, 15]. Similarly, the
HMGA2-NFIB fusions found in pleomorphic adenomas
also contain a stop codon located near but downstream of
the fusion point [19].
The NFIB gene codes for a transcription factor which
recognizes and binds the palindromic sequence 5-TT
GGCNNNNNGCCAA-3 of viral and cellular promoters
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=NFIB
&keywords=NFIB). No functional information is at hand
about the C9orf92 gene (http://www.genecards.org/cgi-bin/
carddisp.pl?gene=C9orf92&keywords=c9orf92).
Although the t(9;12)(p22;q14 ~ 15) thus appears to be
heterogeneous at the molecular level, generating HMGA2-
NFIB in pleomorphic adenoma and lipomas but HMGA2-
C9orf92 in the only myolipoma examined, the pathogenetic
pattern behind these changes is similar to that of HMGA2
rearrangements found generally in benign connective tissue
tumors, i.e., disruption of the HMGA2 locus leaving intact
exons 1–3 which encode the AT-hook domains and sepa-
rates them from the 3´-untranslated region of the gene (3´-
UTR) [20]. The 3´-UTR of HMGA2 was shown to regulate
the transcription of the HMGA2 gene [21, 22].
Conclusion
The present case of myolipoma underscores the frequent
and general role of HMGA2 rearrangements in the genesis
of several benign connective tissue tumors. Further studies
are necessary to find out whether myolipomas of soft tissue
in any systematic way differ from the other tumor types in
the exact manner in which HMGA2 is abrogated, in par-
ticular whether fusion with C9orf92 is a general feature of
these rare neoplasms.
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Additional file 1: Table S1. Cases of myolipomas which have been
reported from 1991 until October 20, 2015. They were found searching
pubmed (http://www.ncbi.nlm.nih.gov/pubmed/) using the term
“myolipoma”. (XLSX 17 kb)
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